Lois Atkins
Lois Atkins is a principal consultant, CMC regulatory affairs at Eli Lilly and Company
Articles
Quality by Design for Biotechnology Products—Part 3
Sally Anliker;Jennifer Mercer;Tim Schofield;Bruce Meiklejohn;Mark Schenerman;Samantha Sheridan;Taruna Arora;Stefanie Pluschkell;Meg Casais;Mark Rosolowsky;Joseph Mezzatesta;Paul Tsang;Jim Precup;Stuart Feldman;Lois Atkins;Bernerd McGarvey;Tony Lubiniecki;Paul Smock;Jutta Look;Anurag S. Rathore
January 1st 2010Regulatory flexibility can make continuous improvement possible.
Quality by Design for Biotechnology Products—Part 1
Sally Anliker;Jennifer Mercer;Tim Schofield;Bruce Meiklejohn;Mark Schenerman;Samantha Sheridan;Taruna Arora;Stefanie Pluschkell;Meg Casais;Mark Rosolowsky;Joseph Mezzatesta;Paul Tsang;Jim Precup;Stuart Feldman;Lois Atkins;Bernerd McGarvey;Tony Lubiniecki;Paul Smock;Jutta Look;Anurag S. Rathore
November 1st 2009First in a three-part series that discusses the complexities of QbD implementation in biotech product development.
Latest Updated Articles
Published: September 11th 2024 | Updated: September 18th 2024
CPHI Pharma Award Finalists Announced for 2024
Published: March 27th 2024 | Updated: June 28th 2024
AbbVie Acquires Landos Biopharma and Gets Full FDA Nod for ADC Product
Published: December 9th 2024 | Updated: December 22nd 2024
Recap Key Industry Trends for Viral Clearance and NGS
Published: December 7th 2024 | Updated: December 22nd 2024
Enhancing Quality Through Training
Published: July 20th 2020 | Updated: December 22nd 2024
Contact BioPharm International Editors
Published: July 19th 2020 | Updated: December 22nd 2024
Editorial Information: BioPharm International Submission Guidelines and Editorial Calendars
